HK Stock Market Move | IMMUNEONCO-B(01541) Rises Over 6% as Major Phase Ib/IIa Clinical Data for IMM0306 Is Disclosed, Expected to Be a Key Driver for Profit Growth

IMMUNEONCO-B(01541) rose over 6% in late trading, up 5.47% as of press time, at HK$3.375, with a turnover of HK$722,600. On the news front, following the receipt of IND clearance from the U.S. FDA for the systemic lupus erythematosus indication on August 21 this year, IMMUNEONCO's independently developed bispecific molecule targeting CD47 and CD20, amulirafusp alfa (IMM0306), has once again reached a milestone positive development. On September 23, IMMUNEONCO announced the latest results of a Phase Ib/IIa clinical study of its independently developed amulirafusp alfa (IMM0306) in combination with Lenalidomide for the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma. It is worth noting that with the disclosure of this significant data for IMM0306 across two indications, the certainty of IMMUNEONCO's differentiated original innovation has been further confirmed. Currently, the drug has received clinical trial approval from the U.S. FDA. In addition to FL and MZL indications, the drug is also being efficiently advanced in clinical development across multiple indication areas including FL, SLE, IgG4-RD, NMOSD, membranous nephropathy, and pSS. In the future, once this potential FIC/BIC product is successfully approved and launched, it is expected to become a key component in IMMUNEONCO's continued enhancement of corporate profits, further opening up more valuation upside for the company.